Dr. Katie Lavigne is an Assistant Professor in the Department of Psychiatry at McGill University and a Researcher at the Douglas Research Centre, where she leads the Douglas Open Science Program. She earned her PhD in Neuroscience from the University of British Columbia in 2018 and completed a postdoctoral fellowship at the Neuro and Douglas in 2023. Her research investigates cognitive dysfunction in psychiatric disorders, using methods ranging from ecological momentary assessment (EMA) to MRI and computational neuroscience, with a focus on open-source cognitive assessment tools.

Dr. Albert Powers, MD, PhD, is an Associate Professor of Psychiatry at Yale University and serves as the Medical and Associate Director of the PRIME Psychosis Risk Clinic. His research focuses on understanding the emergence of psychotic symptoms through computational modeling, neuroimaging, and phenomenological analysis, aiming to inform early diagnosis and intervention strategies.

Dr. Chris Mathys works at the Wellcome Trust Centre for Neuroimaging at UCL and the Max Planck UCL Centre for Computational Psychiatry and Ageing Research. He is a candidate with the Swiss Society for Psychoanalysis, and his research interests include psychoanalysis, neuropsychoanalysis, systems neuroscience, predictive coding, and disorders of the mind.

Dr. Nace Mikus is a Postdoctoral Research Fellow at the Interacting Minds Centre, where he contributes to the Wellcome Trust-funded project Certain About Uncertainty. His research spans clinical psychopharmacology, computational psychiatry, and preclinical rodent studies, with a focus on how uncertainty processing relates to anxiety. He is currently working to develop a computational framework—an “uncertainty fingerprint”—to understand how psychological therapies and medications targeting serotonin and noradrenaline alter the brain’s response to uncertainty.

Dr. Guillermo Horga is an Associate Professor of Psychiatry at Columbia University and the New York State Psychiatric Institute. His lab studies the neurobiological and computational mechanisms of psychotic symptoms in schizophrenia, including sensory and reward-based learning and decision-making. Using behavioral paradigms, fMRI, PET, and pharmacological manipulations, his research aims to understand how dopamine abnormalities and learning dysfunction contribute to hallucinations and delusions, with the goal of developing computational models of psychosis.

Dr. Ariel Rosenfeld is a Koshland Postdoctoral Fellow at the Weizmann Institute of Science in Israel. He holds a Ph.D. in Computer Science from Bar-Ilan University and a B.Sc. in Computer Science and Economics from Tel Aviv University. His research focuses on Human-Agent Interaction, particularly the prediction of human decision-making, and he has published over 20 papers in leading AI conferences and journals. He also lectures at Bar-Ilan University and has over a decade of teaching experience.

Dr. Andreea Diaconescu is a leading figure in computational psychiatry whose interdisciplinary work spans neuroscience, psychology, and clinical psychiatry. Her research leverages advanced mathematical modeling and multimodal imaging to improve early detection, prediction, and intervention for psychosis and suicidality.

Dr. Franziska Knolle is the Principal Investigator of the KnolleLab at the Department of Neuroradiology, Technical University of Munich, where she completed her Habilitation in Neuroscience in June 2024. A former Marie Skłodowska-Curie Fellow, she earned her PhD at the Max Planck Institute for Cognitive and Brain Sciences in Leipzig, focusing on subcortical contributions to predictive processing. After completing her medical studies at TU Dresden, she held postdoctoral positions at the University of Cambridge, studying Huntington’s Disease and the neural mechanisms of psychosis using fMRI and computational approaches.

Dr. Ryan Smith leads a lab at the Laureate Institute for Brain Research (LIBR), where he studies the computational neuroscience of emotion-cognition interactions, with a particular focus on interoception. His work aims to identify differences between mentally healthy and unhealthy individuals to improve diagnosis and treatment selection in psychiatry and clinical psychology.

Dr. James Gilleen is a Senior Lecturer at the University of Manchester, where he leads research on cognitive and symptomatic treatments for schizophrenia. With a background in neuropsychology, his work integrates experimental psychology, pharmacological and non-pharmacological interventions, and advanced neuroimaging techniques to understand and improve cognitive function in psychiatric disorders. He previously held academic and leadership roles at the University of Roehampton and King’s College London, including Programme Director of the MSc Mental Health Studies. A BRC Rising Star and member of the ENIGMA Schizotypy Consortium, Dr. Gilleen is also recognized for excellence in teaching and academic leadership.